Inês Martins, PhD, managing science editor —

The association between excess body fat and increased risk of various cancers is an undisputed fact. Now, the findings of a working group from the International…

Janssen Biotech has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand Darzalex (daratumumab) to include…

Patients with heavily treated multiple myeloma have promising response rates when treated with a combination of selinexor (KPT-330) and low-dose dexamethasone, according to the results…

With advances in treatment for multiple myeloma, some studies have reported improved survival rates, especially among young white patients and, to a lesser extent, in patients…

Empliciti (elotuzumab), a monoclonal antibody, is approved in both the U.S. and Europe as a treatment, in combination with Revlimid (lenalidomide) and Decatron (dexamethasone), for multiple myeloma patients who…

Elotuzumab in combination with bortezomib and dexamethasone prolongs the progression free survival of patients with relapsed or refractory multiple myeloma (RRMM), according to…

The Multiple Myeloma Research Foundation (MMRF) and the University of Michigan have partnered to provide multiple myeloma patients and their doctors access to…

A three-drug combination that includes thalidomide, in place of cyclophosphamide, prior to an autologous stem cell transplant was seen to improve response rates in multiple myeloma patients, according…

The U.S. Food and Drug Administration has designated Darzalex (daratumumab), in combination with standard-of-care regimens, a breakthrough therapy for people with previously treated multiple myeloma (MM), speeding…

A randomized Phase 3 clincal trial has concluded that combining bortezomib (Velcade) with pegylated liposomal doxorubicin (PLD) does not show benefit in treating relapsed or refractory…